GlaxoSmithKline (LON:GSK)‘s stock had its “sell” rating reissued by equities researchers at Societe Generale in a research report issued to clients and investors on Wednesday. They currently have a GBX 1,130 ($15.61) price objective on the stock. Societe Generale’s target price suggests a potential downside of 14.30% from the stock’s previous close.
A number of other research firms also recently weighed in on GSK. BNP Paribas restated a “neutral” rating and issued a GBX 1,580 ($21.83) price objective on shares of GlaxoSmithKline in a report on Tuesday, January 16th. Jefferies Group restated a “buy” rating and issued a GBX 1,500 ($20.72) price objective on shares of GlaxoSmithKline in a report on Tuesday, January 16th. Barclays upgraded GlaxoSmithKline to an “overweight” rating and increased their price objective for the company from GBX 1,450 ($20.03) to GBX 1,650 ($22.80) in a report on Wednesday, January 17th. Liberum Capital restated a “buy” rating and issued a GBX 1,760 ($24.32) price objective on shares of GlaxoSmithKline in a report on Monday, January 15th. Finally, JPMorgan Chase & Co. set a GBX 1,340 ($18.51) price objective on GlaxoSmithKline and gave the company a “neutral” rating in a report on Thursday, January 4th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of GBX 1,530.45 ($21.14).
Shares of GlaxoSmithKline (GSK) opened at GBX 1,318.60 ($18.22) on Wednesday. The firm has a market capitalization of $65,560.00 and a price-to-earnings ratio of 2,487.92. GlaxoSmithKline has a 1-year low of GBX 1,235.20 ($17.07) and a 1-year high of GBX 1,724.50 ($23.83).
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.